{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:12Z","timestamp":1790108772305,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejim.2020.12.010","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T22:16:34Z","timestamp":1610144194000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials."],"prefix":"10.1016","volume":"86","author":[{"given":"Sof\u00eda","family":"Tejada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Sol\u00e9-Lleonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.12.010_bib0001","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14787210.2017.1295847","article-title":"Influenza and other respiratory viruses: standardizing disease severity in surveillance and clinical trials","volume":"15","author":"Rath","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ejim.2020.12.010_bib0002","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc8044","article-title":"Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain","volume":"13","author":"Rello","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.ejim.2020.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.12.010_bib0004","first-page":"461","article-title":"Vaccines against influenza WHO position paper \u2013 November 2012","volume":"87","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.ejim.2020.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ejim.2020.12.010_bib0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016","volume":"146","author":"Gubareva","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejim.2020.12.010_bib0007","unstructured":"European Centre for Disease Prevention and Control (ECDC). Public health use of influenza antivirals during influenza pandemics 2009."},{"key":"10.1016\/j.ejim.2020.12.010_bib0008","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2020.12.010_bib0009","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/jac\/dkx013","article-title":"Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and\/or novel\/variant influenza: a systematic review of the literature, 2009-15","volume":"72","author":"Boikos","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ejim.2020.12.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-020-01347-5","article-title":"Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials","author":"Tejada","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2020.12.010_bib0011","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1093\/jac\/dkx271","article-title":"Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and\/or meta-analyses","volume":"72","author":"Doll","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ejim.2020.12.010_bib0012","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejim.2020.12.010_bib0013","doi-asserted-by":"crossref","first-page":"b5106","DOI":"10.1136\/bmj.b5106","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis","volume":"339","author":"Jefferson","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2020.12.010_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/fampra\/cms059","article-title":"Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials","volume":"30","author":"Ebell","year":"2013","journal-title":"Fam Pract"},{"key":"10.1016\/j.ejim.2020.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.12.010_bib0016","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jac\/dkq158","article-title":"Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ejim.2020.12.010_bib0017","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejim.2020.12.010_bib0018","unstructured":"The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011] n.d. http:\/\/www.cochrane-handbook.org (accessed June 21, 2019)."},{"key":"10.1016\/j.ejim.2020.12.010_bib0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejim.2020.12.010_bib0020","article-title":"Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial","author":"Beigel","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2020.12.010_bib0021","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1473-3099(13)70267-6","article-title":"Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial","volume":"14","author":"Fry","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ejim.2020.12.010_bib0022","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1185\/030079906X80297","article-title":"A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population","volume":"22","author":"Lin","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2020.12.010_bib0023","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.12.010_bib0024","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.12.010_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/0036554021000026981","article-title":"Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza","volume":"35","author":"Puhakka","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ejim.2020.12.010_bib0026","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00044011-200020050-00005","article-title":"Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease","volume":"20","author":"Murphy","year":"2000","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ejim.2020.12.010_bib0027","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/jinf.1999.0602","article-title":"Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study","volume":"40","author":"M\u00e4kel\u00e4","year":"2000","journal-title":"J Infect"},{"key":"10.1016\/j.ejim.2020.12.010_bib0028","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(98)10190-3","article-title":"The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.12.010_bib0029","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group","volume":"337","author":"Hayden","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.12.010_bib0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3851\/IMP2874","article-title":"Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials","volume":"20","author":"Whitley","year":"2015","journal-title":"Antivir Ther (Lond)"},{"key":"10.1016\/j.ejim.2020.12.010_bib0031","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ejim.2020.12.010_bib0032","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2016.07.007","article-title":"A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama","volume":"133","author":"Dawood","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ejim.2020.12.010_bib0033","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/656408","article-title":"Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial","volume":"51","author":"Heinonen","year":"2010","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.ejim.2020.12.010_bib0034","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.inf.0000154322.38267.ce","article-title":"Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma","volume":"24","author":"Johnston","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ejim.2020.12.010_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ejim.2020.12.010_bib0036","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200005000-00005","article-title":"Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial","volume":"19","author":"Hedrick","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ejim.2020.12.010_bib0037","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1093\/cid\/ciu632","article-title":"Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients","volume":"59","author":"de Jong","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejim.2020.12.010_bib0038","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2147\/DDDT.S46654","article-title":"Safety and efficacy of peramivir for influenza treatment","volume":"8","author":"Hata","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejim.2020.12.010_bib0039","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3349\/ymj.2017.58.4.778","article-title":"Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ejim.2020.12.010_bib0040","doi-asserted-by":"crossref","first-page":"g2547","DOI":"10.1136\/bmj.g2547","article-title":"Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Heneghan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2020.12.010_bib0041","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archinte.161.2.212","article-title":"Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials","volume":"161","author":"Lalezari","year":"2001","journal-title":"Arch Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520304532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520304532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:33:51Z","timestamp":1760607231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520304532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":41,"alternative-id":["S0953620520304532"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.12.010","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials.","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}